Clinical Trial

Masitinib in Patients With Mild Alzheimer's Disease

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-09-29; most recent amendment 2025-09-30.
Status change: Recruiting → Not Yet Recruiting 2023-10-06
Status change: Not Yet Recruiting → Recruiting 2023-02-03
Trial Details
NCT Number NCT05564169
Lead Sponsor AB Science
Conditions Alzheimer Disease
Enrollment 600 participants
Start Date 2026-06
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-03